TET3 and leukemia: TET2–/– THP1 cells have a higher sensitivity to Epag compared with the nontargeting gRNA THP1 control cells, suggesting that the inhibition of residual TET activity mostly coming from TET3 may be detrimental for TET2 mutant leukemia cells (32).